Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer

(2021) Sara S. Fois et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

(2020) Paul K. Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

(2020) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018

(2019) Jordi Remon et al.   Journal of Thoracic Oncology

Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA

(2019) Julianna G. Supplee et al.   LUNG CANCER

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

(2018) Neal I. Lindeman et al.   Journal of Thoracic Oncology

Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice

(2018) David Allan Moore et al.   JOURNAL OF CLINICAL PATHOLOGY

Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?

(2014) L. Kim et al.   EUROPEAN RESPIRATORY JOURNAL

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE